These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33023951)

  • 1. A Space-Time Continuum for Immunotherapy Biomarkers in Gastroesophageal Cancer?
    Klempner SJ; Upadhyay V; Chao J
    Clin Cancer Res; 2020 Dec; 26(24):6401-6403. PubMed ID: 33023951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
    Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
    Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting Response and Resistance to Anti-PD-1 Therapy in Microsatellite-Unstable Gastric Cancer.
    Fontana E; Smyth EC
    Cancer Discov; 2021 Sep; 11(9):2126-2128. PubMed ID: 34479973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
    Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
    Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Predictive Value of
    Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
    Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
    Davis AA; Patel VG
    J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
    Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
    Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
    Yarchoan M; Albacker LA; Hopkins AC; Montesion M; Murugesan K; Vithayathil TT; Zaidi N; Azad NS; Laheru DA; Frampton GM; Jaffee EM
    JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30895946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer-Reply.
    Yoon HH; Shi Q; Ajani JA
    JAMA Oncol; 2023 Feb; 9(2):280-281. PubMed ID: 36547945
    [No Abstract]   [Full Text] [Related]  

  • 11. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China.
    Huang J; Mo H; Zhang W; Chen X; Qu D; Wang X; Wu D; Wang X; Lan B; Yang B; Wang P; Zhang B; Yang Q; Jiao Y; Xu B
    Cancer; 2019 Mar; 125(5):742-749. PubMed ID: 30508306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes.
    Jones JO; Smyth EC
    Cancer Treat Rev; 2020 Mar; 84():101950. PubMed ID: 31918022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
    Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
    J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer.
    Amini M; Hejazi M; Ghorban K; Mokhtarzadeh A; Baradaran B
    Gene; 2021 Mar; 772():145376. PubMed ID: 33359128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
    Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
    Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
    Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
    Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.